Sewell stressed that a vital aspect of this ongoing safety testing was to further ensure killer T cells modified with the new TCR recognize cancer cells only.
The T-cell attaches to the MR1 molecule on cancer cells. These T-cells work by assessing potential threats in the body, and the researchers believe that this particular T-cell can be the key to a new type of treatment for cancer. The full study can be found in the journal Nature Immunology. Unlike ordinary anticancer T cells, which fumble over molecular locks involving the human leukocyte antigen (HLA) system, MAIT cells have a TCR that works with another cell surface display system, the monomorphic MHC class I-related protein, MR1.
Scientists at Cardiff University narrate they've found a T-cell with a fresh form of receptor that can acknowledge and extinguish most cancers.
"We originally developed the drug to overcome a problem in some cancers that grow a chaotic barrier of blood vessels in the tumor which prevents the body's immune cells and treatments like chemotherapy entering the tumor", said Professor Ruth Ganss Co-Head of the Cancer and Cell Biology Division at Perth's Harry Perkins Institute of Medical Research.
The researchers at Cardiff compared their discovery to vehicle T-cell therapy but said it could one day be used in more types of cancer.
Adoptive cell transfer relies on "collecting and using patients' own immune cells to treat their cancer", the institute says, and vehicle T-cell therapy, one type of adoptive cell transfer, has advanced the most in clinical trials, with the FDA approving its use in some cases, according to the National Cancer Institute.
Drugs for diabetes, inflammation, alcoholism - and even for treating arthritis in dogs - can also kill cancer cells in the lab, according to a new study.
T cells equipped with the new TCR were shown, in the lab, to kill lung, skin, blood, colon, breast, bone, prostate, ovarian, kidney, and cervical cancer cells, while ignoring healthy cells. This is the receptor that enables the cells to detect and fight the cancer.
Also, Sewell did not dismiss the idea that lots of people could have the cancer-immune cells or that most people have the cell, but the "receptor has not activated yet".
Additionally, more analysis into how fashioned these T-cells are is fundamental, he acknowledged.
They tested all compounds in the Hub on 578 human cancer cell lines from the Broad's Cancer Cell Line Encyclopedia and tagged each cell line with a DNA barcode, allowing them to pool several cell lines together in each dish.
"It's one T-cell clone that they worked with so we need to see if we can find more of these T-cells and can we find it in everybody", van den Brink said.
"There's a chance here to treat every patient", said researcher Andrew Sewell, to the BBC.